Skip to main content
Fig. 4 | Chinese Medicine

Fig. 4

From: Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro

Fig. 4

The therapeutic effect of LS or remdesivir on SARS-CoV-2-infected mice. A The survival rate was observed for 5 days after viral infection. B The pulmonary viral load at the fifth d.p.i. was determined by TCID50. C Histopathological changes of lung tissues at the fifth d.p.i. Scale bar = 100 µm. a Mock infected mice treated with PBS (normal control, NC); b SARS-CoV-2-infected mice treated with PBS (viral control, Virus); c SARS-CoV-2-infected mice treated with remdesivir (50 mg/kg); df SARS-CoV-2-infected mice treated with LS (160, 80 and 40 mg/kg). *p < 0.05; **p < 0.01; ***p < 0.001, compared with viral control

Back to article page